News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
July, 2025
July 2025
M T W T F S S
 123456
78910111213
14151617181920
21222324252627
28293031  
Lung Cancer Survival Has More Than Doubled – Lung Cancer Europe
Photo: depositphotos.com
Jun 30, 2025, 22:18

Lung Cancer Survival Has More Than Doubled – Lung Cancer Europe

Lung Cancer Europe shared a post on LinkedIn:

“Lung cancer survival has more than doubled.
New real-world data from public hospitals in France shows 3-year survival for lung adenocarcinoma rose from 16.3% (2000) to 38.6% (2020) – driven by earlier diagnosis and targeted treatment.
Median survival also increased, from 8.5 months to 20.7 months.
These aren’t trial results – this is real-world care, and it’s changing outcomes.
And while the data comes from France, it matters far beyond. It shows what’s possible when health systems deliver timely diagnosis, molecular testing, and access to the right treatment.
This is what progress looks like. But it must reach everyone who needs it.”

Title: Survival of Patients with Lung Adenocarcinoma Diagnosed in 2000, 2010, and 2020

Authors: Didier Debieuvre, Lionel Falchero, Olivier Molinier, Sébastien Couraud, Alexis Cortot, Nicolas Meyer, Bernard Asselain, Etienne Auvray, Dorine Templement-Grangerat, Acya Bizieux, Jean Tredaniel, Sophie Schneider, Jean-Bernard Auliac, Olivier Bylicki, Alexia Letierce, Hugues Morel

You can read the Full Article on NEJM Evidence 

Lung Cancer Survival Has More Than Doubled - Lung Cancer Europe

More posts featuring Lung Cancer Europe.

 

Acya Bizieux Alexia Letierce Alexis Cortot Bernard Asselain cancer Didier Debieuvre Dorine Templement-Grangerat Etienne Auvray Hugues Morel Jean Tredaniel Jean-Bernard Auliac Lionel Falchero Lung cancer Lung Cancer Europe Nicolas Meyer Olivier Bylicki Olivier Molinier OncoDaily Oncology Sébastien Couraud Sophie Schneider
Special Coverage
Oncolibrary
Jul 2, 2025, 14:00
ESMO GI 2025 Highlights: OrigAMI-1 Trial on Amivantamab Rechallenge in mCRC
Blog
Jul 2, 2025, 13:41
Kenji López-Cuevas Congratulates Andreas Charalambous on His Appointment as Chairman of the SPCC
Blog
Jul 2, 2025, 13:25
Julie Ince-Demetriou: On 7th July Inaugural Pink Sky Grants Scheme Will Open to EOI Applications
Blog
Jul 2, 2025, 13:19
Korede Akindele: Sarcoma May Be Rare But Survival Shouldn’t Be
Blog
Jul 2, 2025, 13:08
Irini Agapidaki on the Critical Role of Prevention and the National Program 'Prolamvano'
Blog
Jul 2, 2025, 12:57
Mehmet Murat Zerey: I am Starting a New Position as an Advanced Genitourinary Oncology Clinical Fellow at Vanderbilt University Medical Center
Insight
Jul 2, 2025, 12:37
Wafaa M Rashed: New on the PAPERI Blog - Epigenetics and Maternal Nutrition in Africa as a Public Health Priority
Blog
Jul 2, 2025, 12:32
Sergio Cifuentes Canaval: What it Means to Build a Career in Oncology From Latin America
Blog
Jul 2, 2025, 12:21
We Managed to Give Unforgettable Moments to Girls and Boys of the Hospital Infantil of Mexico 'Federico Gómez' - Cancer Warriors Foundation of Mexico
Blog
Jul 2, 2025, 11:46
Lucrecia Ruiz: I’m Starting a New Position as Head of the Melanoma, Head and Neck Cancer, and Neuro-Oncology Section at MD Anderson Madrid
Oncolibrary
Jul 2, 2025, 11:40
ESMO GI 2025 Highlights: BXCL701 + Pembrolizumab in Second-Line Advanced PDAC
Blog
Jul 2, 2025, 11:38
Memorial Sloan Kettering Cancer Center Congratulates Its Awardees